Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The deal centers on an exciting cardiovascular health ...

Verve Therapeutics stock rallied 75% in Monday’s after-hours trading in reaction to the news. If finalized, the deal would boost Eli Lilly’s pipeline of experimental drugs.

Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Market-moving news hits ...

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.

Eli Lilly (NYSE: LLY), a prominent player in the pharmaceuticals industry with a market capitalization of $710 billion, has reached an agreement to acquire Verve Therapeutics (NASDAQ: VERV), marking ...

Asian shares are mixed and oil prices have advanced after the escalation of conflict in the Middle East hit Wall Street. Japan reported that its exports fell in May as the auto industry was hit ...